Neuragen Clinical Studies
Neuragen® has been recommended by health care professionals in the USA and Canada since 1996 for the treatment of chronic nerve pain associated with a variety of conditions.
We recommend that you consult your health care professional about combining Neuragen with your current treatment. Ask your health care professional to request the results of these clinical studies.
Clinical Trials
Four clinical trials of Neuragen have been completed to date, with a fifth trial in progress. In all trials to date, Neuragen provided rapid and effective pain relief without significant side effects.
LSU Clinical Trial Spring 2008
Sixty subjects with all cause neuropathic pain in the feet were treated in a double blind placebo controlled trial by independent researchers at Louisiana State University. The graph below represents the percentage of people who experienced significant pain relief with Neuragen vs placebo 30 minutes after application.
In a more detailed analysis, 52% of subjects treated with Neuragen experienced at least a 50% reduction in pain within 30 minutes vs only 3% of the patients treated with a placebo.
Statistical analysis also revealed that the effects of the experimental
treatments were not affected by the usage of other pain analgesics for
neuropathy such as anti-convulsants and anti-depressants.
In a separate analysis of just the diabetics in the group, it was found that the diabetics experienced the same pain relieving benefits as the group as a whole.
LSU Clinical Trial Fall 2007
Forty subjects with all cause neuropathic pain in the feet were treated in a double blind placebo controlled trial by independent researchers at Louisiana State University. The graph below represents the average pain level for all participants before treatment (time=0) and for up to 9 hours after treatment with either Neuragen (blue drops) or placebo (green triangles). Pain relief with Neuragen was statistically significant over placebo and for up to 8 hours in duration.
Another commonly accepted way to analyze data from pain trials is to compare the number of patients who received at least a 50% reduction in pain level vs. placebo. As shown on the left, 63% of subjects receiving Neuragen benefited from a 50% or greater reduction in pain, vs. only 15% in the placebo group.
LSU Clinical Trial Fall 2006
In a separate clinical trial also done at Louisiana State University, subjects with peripheral neuropathy received either Neuragen or no treatment over a six week intervention, as part of a larger peripheral neuropathy intervention study. Pain level was monitored on a 0-10 scale three times every week, before treatment, after treatment, and after a one-hour tai chi exercise session. As shown in the graph below, the application of Neuragen significantly reduced pain levels within five minutes and the pain relief lasted for at least one hour. Also noted was that Neuragen treatment resulted in improved physical performance and the ability to participate in tai chi exercises.
Diabetic Neuropathy Trial
People suffering with diabetic peripheral neuropathy with pain of at least 3 months duration were invited to participate in an open label trial of Neuragen for temporary pain relief. Subjects were recruited from a California neuropathy support group, and instructed to apply Neuragen topically to the maximally painful area at least six times in one month, and complete one patient diary for each application. Efficacy was measured primarily by reduction in pain intensity over the first six hours, compared with the pain intensity before the application. Overall, 29 patients satisfactorily completed the survey. Of these, 20 patients (69%) noted some improvement in pain, with 17 patients (59%) noting a remarkable 50-100% improvement, usually within minutes.
Repeated use of Neuragen decreased overall levels of pain for some patients allowing them to use less medication overall. Also, improvement in quality of life was associated with efficacy of Neuragen including improved sleep, ability to work, social life, improved energy, and a reduction in the tendency to depressed mood.
|
